HORIZON EUROPE
Europeo
Specific Challenge:‘Organ-on-Chip’ (OoC) is a promising technology for achieving more effective in-vitro research in a broad range of life science sectors, including medicine and pharmacy, cosmetics, agriculture and food, and for chemical safety testing including regulatory testing. More effective drug development, efficacy and safety screening, would reduce the need for animal testing and clinical testing. Nevertheless, much more research and development is needed to develop more robust, automated and parallelised OoC technologies that are applicable in industry, with medium to high throughput capacity, reliability and repeatability, using validated and standardised tools and methods.
Scope:Multidisciplinary research for the development of Organ-on-Chip technologies able to mimic human organs and organ-systems, based on integrated platforms involving technologies such as: cell culturing (including multi-tissue or multi-organ arrangements), micro-fluidics, micro/nano-sensors, imaging, actuators, 3D bio-printing, modelling and simulation, bioinformatics;Demonstrator applications involving modelling, diagnosis and therapy of human disease(s) of high and yet unmet...
ver más
Specific Challenge:‘Organ-on-Chip’ (OoC) is a promising technology for achieving more effective in-vitro research in a broad range of life science sectors, including medicine and pharmacy, cosmetics, agriculture and food, and for chemical safety testing including regulatory testing. More effective drug development, efficacy and safety screening, would reduce the need for animal testing and clinical testing. Nevertheless, much more research and development is needed to develop more robust, automated and parallelised OoC technologies that are applicable in industry, with medium to high throughput capacity, reliability and repeatability, using validated and standardised tools and methods.
Scope:Multidisciplinary research for the development of Organ-on-Chip technologies able to mimic human organs and organ-systems, based on integrated platforms involving technologies such as: cell culturing (including multi-tissue or multi-organ arrangements), micro-fluidics, micro/nano-sensors, imaging, actuators, 3D bio-printing, modelling and simulation, bioinformatics;Demonstrator applications involving modelling, diagnosis and therapy of human disease(s) of high and yet unmet medical need. The new devices should permit the simulation of body system processes under adverse conditions and in particular in disease states, healing and regeneration under mechanical stress and electrical stimulation, or immune responses, taking into account sex and gender differences, when relevant;Industrial development/piloting towards improved robustness, reliability, scalability, parallelisation and standardisation of tools and methods, and providing interfaces to standard laboratory equipment;Taking into account medical regulatory requirements. A related topic (SC1-BHC-11-2020: Advancing the safety assessment of chemicals without the use of animal testing) is published under the part "Health, demographic change and wellbeing" of the work Programme.[1]
Proposals submitted under this topic should include a business case and exploitation strategy, as outlined in the Introduction to the LEIT part of this Work Programme.
Activities should start at TRL 3 and achieve TRL 5 at the end of the project.
Please note that this topic will take the form of lump sums as defined in Commission Decision C(2017)7151 of 27 October 2017[2]. Details of the lump sum funding pilot scheme are published on the Funding & Tenders Portal[3] together with the specific Model Grant Agreement for Lump Sums[4] applicable.
The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected Impact:Verifiable progress in the application of Organ-on-Chip technologies for in-vitro research;Reduction of the need for animal and clinical testing;Lowering of barriers for application of Organ-on-Chip technology;Improved competitiveness and attractiveness of the European biomedical and healthcare sector;Increased awareness and knowledge about medical regulatory policies and requirements, especially by academics and SMEs.
Cross-cutting Priorities:Gender
[1]http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-health_en.pdf
[2]http://ec.europa.eu/research/participants/data/ref/h2020/other/legal/lump_sum/lumpsumdecision-2017-7151_en.pdf
[3]http://ec.europa.eu/research/participants/docs/h2020-funding-guide/grants/applying-for-funding/find-a-call/what-you-need-to-know_en.htm
[4]http://ec.europa.eu/research/participants/data/ref/h2020/mga/lumpsum/h2020-mga-lumpsum-pilot-multi_en.pdf
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
Described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions:
Described in Annex B and Annex C of the Work Programme.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
Under 3 (a) Proposals are first ranked in separate lists according to the topics against which they were submitted (‘topic ranked lists’). When comparing ex aequo proposals from different topics, proposals having a higher position in their respective 'topic ranked list' will be considered to have a higher priority in the overall ranked list.
Under 3 (b) For all topics and types of action, the prioritisation will be done first on the basis of the score for Impact, and then on that for Excellence.
Described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions:
Described in Annex B and Annex C of the Work Programme.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
Under 3 (a) Proposals are first ranked in separate lists according to the topics against which they were submitted (‘topic ranked lists’). When comparing ex aequo proposals from different topics, proposals having a higher position in their respective 'topic ranked list' will be considered to have a higher priority in the overall ranked list.
Under 3 (b) For all topics and types of action, the prioritisation will be done first on the basis of the score for Impact, and then on that for Excellence.
Proposals submitted under these topics should include a business case and exploitation strategy, as outlined in the Introduction to the LEIT part of this Work Programme.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (two-stage call):
For stage 1: maximum 3 months from the deadline for submission.
For stage 2: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
- Lump sum pilot MGA – multi: https://ec.europa.eu/research/participants/data/ref/h2020/mga/lumpsum/h2020-mga-lumpsum-pilot-multi_en.pdf
- Commission decision C(2017)7151: https://ec.europa.eu/research/participants/data/ref/h2020/other/legal/lump_sum/lumpsumdecision-2017-7151_en.pdf
- PDF template Part A + Part B for RIA and IA Lump sum: https://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/pt/2018-2020/h2020-call-pt-ria-ia-ls2-2018-20_en.pdf
- PDF template of the Excel workbook: https://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/pt/2018-2020/h2020-call-pt-budget-ria-ia-csa-ls2-2018-20_en.pdf
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply
Please note that this topic will take the form of lump sums as defined in Commission Decision C(2017)7151 of 27 October 2017[[http://ec.europa.eu/research/participants/data/ref/h2020/other/legal/lump_sum/lumpsumdecision-2017-7151_en.pdf]]. Details of the lump sum funding pilot scheme are published on the Funding & Tenders Portal[[http://ec.europa.eu/research/participants/docs/h2020-funding-guide/grants/applying-for-funding/find-a-call/what-you-need-to-know_en.htm]] together with the specific Model Grant Agreement for Lump Sums[[http://ec.europa.eu/research/participants/data/ref/h2020/mga/lumpsum/h2020-mga-lumpsum-pilot-multi_en.pdf]] applicable.
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
8. Additional documents:
Please note that this topic will take the form of lump sums as defined in Commission Decision C(2017)7151 of 27 October 2017.
Details of the lump sum funding pilot scheme are published on the Funding & Tenders Portal together with the specific Model Grant Agreement for Lump Sums applicable.
1. Introduction WP 2018-20
5. Introduction to Leadership in enabling and industrial technologies (LEITs) WP 2018-20
5ii. Nanotechnologies, advanced materials, advanced manufacturing and processing, biotechnology WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
Set of slides ‘Lump sum pilots: what do I have to know?’ (for informing applicants): https://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/agd/h2020-ls-pilots-guide_en.pdf
Video ‘All I need to know about lump sum pilots’: https://www.youtube.com/watch?v=VTSy8T2_yHg&feature=youtu.be
Guidance note for Option II pilots (excepted INNOSUP): https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/h2020-guide-note-lumpsum-option-2_en.pdf
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta